Skip to main content

Mood Disorders

9
Pipeline Programs
6
Companies
6
Clinical Trials
4
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
3
0
1
4
Early DiscoveryClinical DevelopmentMarket

On Market (4)

Approved therapies currently available

GSK
LAMICTALApproved
lamotrigine
GSK
Anti-epileptic Agent [EPC]oral1994
112M Part D
GSK
LAMICTAL XRApproved
lamotrigine
GSK
Anti-epileptic Agent [EPC]oral2009
53M Part D
GSK
LAMICTAL ODTApproved
lamotrigine
GSK
Anti-epileptic Agent [EPC]oral2009
3M Part D
GSK
LAMICTAL CDApproved
lamotrigine
GSK
Anti-epileptic Agent [EPC]oral1998

Competitive Landscape

6 companies ranked by most advanced pipeline stage

GSK
GSKLONDON, United Kingdom
1 program
1
LamotriginePHASE_31 trial
Active Trials
NCT00579982Completed97Est. Feb 2008
ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
1
LamotriginePhase 3
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
3 programs
1
1
High Intensity TrainingPhase 21 trial
Family-Focused Treatment with MCC AppPhase 1/21 trial
cognitive behavioral therapyN/A1 trial
Active Trials
NCT05070052Completed66Est. Mar 2022
NCT03913013Completed65Est. Oct 2021
NCT02097563Completed133Est. Jan 2019
Innovation Pharmaceuticals
1 program
1
ErythropoietinPhase 21 trial
Active Trials
NCT00916552Completed83Est. Oct 2012
Young BioPharma
Young BioPharmaMA - Lowell
1 program
1
short-term dynamic therapyPhase 21 trial
Active Trials
NCT00521417Unknown140Est. Aug 2020
Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
1 program
ErythropoietinPHASE_2

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
GSKLamotrigine
Angeles TherapeuticsHigh Intensity Training
Innovation PharmaceuticalsErythropoietin
Young BioPharmashort-term dynamic therapy
Angeles TherapeuticsFamily-Focused Treatment with MCC App
Angeles Therapeuticscognitive behavioral therapy

Clinical Trials (6)

Total enrollment: 584 patients across 6 trials

NCT00579982GSKLamotrigine

An Open-Label Trial Measuring Satisfaction And Convenience Of Two Formulations Of Lamotrigine In Subjects With A Mood Disorder

Start: Jan 2008Est. completion: Feb 200897 patients
Phase 3Completed
NCT02097563Angeles TherapeuticsHigh Intensity Training

Family-Focused Therapy for Youth With Early-Onset Bipolar or Psychotic Disorders

Start: Jun 2014Est. completion: Jan 2019133 patients
Phase 2Completed

Effects of Erythropoietin on Depressive Symptoms and Neurocognitive Deficits in Depression and Bipolar Disorder

Start: Sep 2009Est. completion: Oct 201283 patients
Phase 2Completed
NCT00521417Young BioPharmashort-term dynamic therapy

Short- and Long-term Group Psychotherapy

Start: Aug 2005Est. completion: Aug 2020140 patients
Phase 2Unknown
NCT03913013Angeles TherapeuticsFamily-Focused Treatment with MCC App

Technology Enhanced Family Treatment

Start: Nov 2018Est. completion: Oct 202165 patients
Phase 1/2Completed
NCT05070052Angeles Therapeuticscognitive behavioral therapy

MBCT and CBT for Youth at High Risk for Mood and Psychotic Disorders: a Randomized Controlled Trial

Start: Jan 2020Est. completion: Mar 202266 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.